Legal & General Group Plc boosted its position in Hologic, Inc. (NASDAQ:HOLX) by 6.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,377,892 shares of the medical equipment provider’s stock after buying an additional 84,516 shares during the period. Legal & General Group Plc owned approximately 0.49% of Hologic worth $62,533,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Victory Capital Management Inc. raised its stake in Hologic by 418.5% in the first quarter. Victory Capital Management Inc. now owns 4,050,824 shares of the medical equipment provider’s stock worth $172,363,000 after buying an additional 3,269,503 shares during the last quarter. American Century Companies Inc. raised its stake in Hologic by 229.4% in the first quarter. American Century Companies Inc. now owns 3,164,928 shares of the medical equipment provider’s stock worth $134,668,000 after buying an additional 2,204,085 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Hologic by 229.7% in the second quarter. Russell Investments Group Ltd. now owns 1,059,586 shares of the medical equipment provider’s stock worth $48,100,000 after buying an additional 738,215 shares during the last quarter. Pictet Asset Management Ltd. raised its stake in Hologic by 69.4% in the first quarter. Pictet Asset Management Ltd. now owns 1,585,461 shares of the medical equipment provider’s stock worth $67,461,000 after buying an additional 649,632 shares during the last quarter. Finally, Quantitative Investment Management LLC raised its stake in Hologic by 133.7% in the first quarter. Quantitative Investment Management LLC now owns 504,800 shares of the medical equipment provider’s stock worth $21,479,000 after buying an additional 288,800 shares during the last quarter. 94.43% of the stock is currently owned by institutional investors.

Shares of Hologic, Inc. (NASDAQ:HOLX) opened at 37.91 on Friday. The stock’s 50 day moving average price is $41.66 and its 200 day moving average price is $42.74. The stock has a market capitalization of $10.63 billion, a price-to-earnings ratio of 14.12 and a beta of 0.90. Hologic, Inc. has a 12 month low of $35.15 and a 12 month high of $46.80.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. The firm had revenue of $806.10 million during the quarter, compared to analysts’ expectations of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The business’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.51 EPS. Analysts expect that Hologic, Inc. will post $2.01 EPS for the current year.

WARNING: “Legal & General Group Plc Boosts Stake in Hologic, Inc. (HOLX)” was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://theolympiareport.com/2017/08/27/legal-general-group-plc-boosts-stake-in-hologic-inc-holx.html.

A number of research firms recently commented on HOLX. BidaskClub lowered Hologic from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. Barclays PLC reissued an “equal weight” rating and issued a $51.00 price target (down from $53.00) on shares of Hologic in a research report on Wednesday, August 9th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $45.00 price target (down from $50.00) on shares of Hologic in a research report on Wednesday, August 9th. Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Finally, Deutsche Bank AG lowered their price target on Hologic from $51.00 to $49.00 and set a “buy” rating for the company in a research report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $48.64.

In other news, Director Elaine Ullian sold 8,938 shares of the firm’s stock in a transaction on Friday, June 2nd. The stock was sold at an average price of $43.99, for a total value of $393,182.62. Following the completion of the sale, the director now owns 23,810 shares of the company’s stock, valued at approximately $1,047,401.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Peter J. Valenti III sold 10,005 shares of the firm’s stock in a transaction on Tuesday, May 30th. The stock was sold at an average price of $43.44, for a total value of $434,617.20. Following the completion of the sale, the insider now directly owns 20,994 shares of the company’s stock, valued at approximately $911,979.36. The disclosure for this sale can be found here. Insiders sold a total of 42,358 shares of company stock valued at $1,849,803 in the last three months. Insiders own 0.79% of the company’s stock.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.